Drug Profile
Research programme: neurodegenerative disorders therapeutics - AbCellera Biologics/Denali Therapeutics
Latest Information Update: 28 Jul 2022
Price :
$50
*
At a glance
- Originator Abcellera; Denali Therapeutics Inc
- Class Monoclonal antibodies; Neuroprotectants
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Neurodegenerative disorders; Neurological disorders
Most Recent Events
- 28 Jul 2022 No recent reports of development identified for research development in Neurodegenerative-disorders in USA (Parenteral)
- 28 Mar 2022 No recent reports of development identified for research development in Neurological-disorders in Canada (Parenteral)
- 28 Mar 2022 No recent reports of development identified for research development in Neurological-disorders in USA (Parenteral)